Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Inhibition of Purine Nucleoside Phosphorylase Is a Promising Anti-Sickling Approach for Sickle Cell Disease

Adekunle Emmanuel Alagbe, Lynda Little-Ihrig, Brian J Philips, Stephanie M Mutchler, Julia Z Xu, Edwin K Jackson, Stevan Tofovic, Enrico M Novelli

Blood (2024) 144 (Supplement 1): 3861.

https://doi.org/10.1182/blood-2024-199595

Published: 2024

Journal Articles

A Phase 1b/2 Study of the Efficacy and Safety of Combination Hydroxyurea and Dose-Escalated Erythropoietin for Treatment of Anemia in Sickle Cell Disease (ACHiEvE-SCD)

Titilope A Adeyemo, Nelly Kiriza, Feyisayo T. Oluwole, Mark Jelinek, Jude Jonassaint, Olubusola Oluwole, Christine Saber, Brian J Philips, Olusegun-Joseph D Akinsanya, Vincent O Osunkalu, Laura M. DeCastro, Enrico M Novelli, Julia Z Xu

Blood (2024) 144 (Supplement 1): 178.

https://doi.org/10.1182/blood-2024-205261

Published: 2024

Journal Articles

Results from a Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tebapivat (AG-946) in Patients with Sickle Cell Disease

Julia Z Xu, Enrico M Novelli, Jean-Antoine Ribeil, Andreas Glenthøj, Srila Gopal, Hanny Al-Samkari, Modupe Idowu, Jenny Despotovic, Spurthi Patil, Xiaoshu Dai, Abdullah Al Masud, Michael Callaghan, Fuad El Rassi

Blood (2024) 144 (Supplement 1): 2496.

https://doi.org/10.1182/blood-2024-203509

Published: 2024

Journal Articles

Feasibility of Near-Infrared Spectroscopy for Monitoring Hemodynamic Changes in Patients with Sickle Cell Disease Treated with Mitapivat

Timothy Quang, Julia Z Xu, Ingrid Frey, Kathryn Jaroszynski, Elise M. Berning, Anna Conrey, Ruth Pierre Charles, Brian Y Hill, Neal Jeffries, Swee Lay Thein, Bruce J. Tromberg

Blood (2022) 140 (Supplement 1): 2526–2527.

https://doi.org/10.1182/blood-2022-159559

Published: 2022

Journal Articles

The Pyruvate Kinase Activator Mitapivat Improves Red Blood Cell Deformability and Sickling Kinetics in Adult Patients with Sickle Cell Disease

Maureen Lundt, Nancy Asomaning, Ingrid Frey, Xunde Wang, Anna Conrey, Julia Z Xu, Quan Li, Emily B Dunkelberger, Neal Jeffries, William Eaton, Swee Lay Thein

Blood (2022) 140 (Supplement 1): 2508–2509.

https://doi.org/10.1182/blood-2022-170010

Published: 2022

Journal Articles

Inhibition of Hypoxia Inducible Factor Prolyl Hydroxylase By FG-4592 (Roxadustat) Increases Erythropoietic Stimulation in a Mouse Model of Sickle Cell Disease

Malini Sharma, Timothy Lequang, Brian J Philips, Fabliha A Chowdhury, Katherine C Wood, Adam C Straub, Julia Z Xu

Blood (2022) 140 (Supplement 1): 5391–5392.

https://doi.org/10.1182/blood-2022-164803

Published: 2022

Journal Articles

A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease

Blood (2022) 140 (19): 2053–2062.

https://doi.org/10.1182/blood.2022015403

Published: 2022

Includes: Supplemental data

Journal Articles

Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study

Julia Z. Xu, Anna Conrey, Ingrid Frey, Eveline Gwaabe, Laurel A Menapace, Laxminath Tumburu, Maureen Lundt, Quan Li, Kristen Glass, Varsha Iyer, Heidi Mangus, Charles Kung, Lenny Dang, Penelope A. Kosinski, Peter Hawkins, Neal Jeffries, William Eaton, Swee Lay Thein

Blood (2021) 138 (Supplement 1): 10.

https://doi.org/10.1182/blood-2021-145398

Published: 2021

Journal Articles

Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137716

Published: 2020

Journal Articles

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Blood (2020) 135 (11): 791–803.

https://doi.org/10.1182/blood.2019003988

Published: 2020

Includes: Supplemental data

Journal Articles

Quality Improvement Initiative: Improving Time to First Dose in a Sickle Cell Infusion Center

Foluso Joy Ogunsile, MD, Julia Z. Xu, MD MSc, Elizabeth Brown, Elizabeth Williams, BA, Sophie M. Lanzkron, MD

Blood (2019) 134 (Supplement_1): 3404.

https://doi.org/10.1182/blood-2019-131970

Published: 2019

Journal Articles

Identification of Optimal Thalassemia Screening Strategies for Migrant Populations in Thailand: A Mixed-Methods Approach

Julia Z. Xu, MD MSc, Meghan Foe, Wilaslak Tanongsaksakul, MD, Thidarat Suksangpleng, PhD, Supachai Ekwattanakit, PhDMD, Suchada Riolueang, MSc, Marilyn J. Telen, MD, Bonnie N. Kaiser, PhD, Vip Viprakasit, MD DPhil

Blood (2019) 134 (Supplement_1): 2112.

https://doi.org/10.1182/blood-2019-131805

Published: 2019

Journal Articles

International Multi-Site Clinical Validation of Point-of-Care Microchip Electrophoresis Test for Hemoglobin Variant Identification

Blood (2019) 134 (Supplement_1): 3373.

https://doi.org/10.1182/blood-2019-129336

Published: 2019

Journal Articles

Systemic mastocytosis with an associated hematological neoplasm masquerading as overt primary myelofibrosis

Rebecca Z. Xu, Zhaodong Xu

Blood (2018) 132 (24): 2613.

https://doi.org/10.1182/blood-2018-09-875914

Published: 2018

Journal Articles

Knowledge, Cultural, and Structural Barriers to Thalassemia Screening in Migrant Populations in Thailand

Julia Z. Xu, MD MScGH, Wilaslak Tanongsaksakul, MD, Thidarat Suksangpleng, PhD, Supachai Ekwattanakit, PhD MD, Suchada Riolueang, MSc, Bonnie N. Kaiser, PhD, Nathan M. Thielman, MD, Marilyn J. Telen, MD, Vip Viprakasit, MD DPhil

Blood (2018) 132 (Supplement 1): 2228.

https://doi.org/10.1182/blood-2018-99-114117

Published: 2018

Journal Articles

Factors Related to the Progression of Sickle Cell Disease Nephropathy

Julia Z. Xu, MD, Melanie E. Garrett, MS, Karen L. Soldano, BS, Sean T. Chen, Allison E. Ashley-Koch, PhD, Marilyn J. Telen, MD

Blood (2016) 128 (22): 9.

https://doi.org/10.1182/blood.V128.22.9.9

Published: 2016

Journal Articles

Abundant expression of transcription factor GATA-2 in proliferating but not in differentiated mast cells in tissues of mice: demonstration by in situ hybridization

T Jippo, H Mizuno, Z Xu, S Nomura, M Yamamoto, Y Kitamura

Blood (1996) 87 (3): 993–998.

https://doi.org/10.1182/blood.V87.3.993.bloodjournal873993

Published: 1996

NARROW

Inhibition of Purine Nucleoside Phosphorylase Is a Promising Anti-Sickling Approach for Sickle Cell Disease

A Phase 1b/2 Study of the Efficacy and Safety of Combination Hydroxyurea and Dose-Escalated Erythropoietin for Treatment of Anemia in Sickle Cell Disease (ACHiEvE-SCD)

Results from a Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tebapivat (AG-946) in Patients with Sickle Cell Disease

Feasibility of Near-Infrared Spectroscopy for Monitoring Hemodynamic Changes in Patients with Sickle Cell Disease Treated with Mitapivat

The Pyruvate Kinase Activator Mitapivat Improves Red Blood Cell Deformability and Sickling Kinetics in Adult Patients with Sickle Cell Disease

Inhibition of Hypoxia Inducible Factor Prolyl Hydroxylase By FG-4592 (Roxadustat) Increases Erythropoietic Stimulation in a Mouse Model of Sickle Cell Disease

A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease

Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study

Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Quality Improvement Initiative: Improving Time to First Dose in a Sickle Cell Infusion Center

Identification of Optimal Thalassemia Screening Strategies for Migrant Populations in Thailand: A Mixed-Methods Approach

International Multi-Site Clinical Validation of Point-of-Care Microchip Electrophoresis Test for Hemoglobin Variant Identification

Systemic mastocytosis with an associated hematological neoplasm masquerading as overt primary myelofibrosis

Knowledge, Cultural, and Structural Barriers to Thalassemia Screening in Migrant Populations in Thailand

Factors Related to the Progression of Sickle Cell Disease Nephropathy

Abundant expression of transcription factor GATA-2 in proliferating but not in differentiated mast cells in tissues of mice: demonstration by in situ hybridization

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only